Floatz logo

Dfn-15

Thoracic Sarcomas

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Thoracic Sarcomas cohort.

Asset / SponsorPhaseRating
Iscomatrix Adjuvant
National Cancer Institute (NCI)
Phase 1/2CCC
Montanide Isa 51
National Cancer Institute (NCI)
Phase 1/2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 1/2CCC
h1299 cell lysates
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →